Levodopa and dopamine agonist phobia in Parkinson’s Disease — does it really matter? A survey on treatment patterns in Polish tertiary centres
Levodopa remains the gold standard in PD treatment in tertiary movement disorder centres in Poland. Dopamine agonists formed the second most frequently prescribed group of medications; however, the observed low dosages of both levodopa and dopamine agonists may suggest a cautious approach by clinicians. Amantadine and MAO-B inhibitors (mainly rasagiline) constituted important elements of PD pharmacotherapy. The high prevalence of complex polytherapy underlines the complexity of PD management, the cautious use of single medication at high doses, and the need for personalised therapeutic strategies.
Authors
- Jarosław Sławek (ORCID: https://orcid.org/0000-0001-6816-0877)
- Katarzyna Śmiłowska (ORCID: https://orcid.org/0000-0001-9167-1624)
- Michał Schinwelski (ORCID: https://orcid.org/0000-0003-3695-2612)
- Jakub Kasprzak (ORCID: https://orcid.org/0000-0002-7805-8881)
- Magdalena Kwaśniak-Butowska (ORCID: https://orcid.org/0000-0002-2322-3376)
- Jarosław Dulski (ORCID: https://orcid.org/0000-0002-5517-9875)
- Filip Przytuła
- Witold Sołtan
- Dariusz Koziorowski (ORCID: https://orcid.org/0000-0001-8920-8024)
- Anna Roszmann (ORCID: https://orcid.org/0000-0003-3865-3667)
Institutions
- Jacksonville College (US)
- Copernicus Memorial Hospital (PL)
- Neuro Device (Poland) (PL)
- Mayo Clinic in Florida (US)
- Gdańsk Medical University (PL)
Publication Details
- Journal
- Neurologia i Neurochirurgia Polska
- Published
- 2025-02-26
- DOI
- https://doi.org/10.5603/pjnns.103168
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39